Johnson & Johnson’s head of R&D has been jettisonedAugust 09, 2022 - Johnson & Johnson’s head of R&D is off. In a surprise post-market announcement yesterday, the company revealed that its executive vice president of pharma R&D Mathai Mammen, M.D., Ph.D, is leaving to “pursue other opportunities.”
He moved over from Merck & Co., where he oversaw research across cardiovascular and metabolic diseases, as well as immunology and oncology. Before that, Mammen headed up R&D at Theravance, a small molecule-focused biotech he co-founded in 1996.
https://www.fiercebiotech.com/biotech/jjs-head-rd-mathai-mammen-heads-exit-surprise-move
[ It is apparent that Mammen has the wrong skill sets and experience to have J&J become a player in the emerging field of immuno-oncology notwithstanding the recent approval of the CAR-T agent Carvykti. ]